154 related articles for article (PubMed ID: 24451646)
41. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
[TBL] [Abstract][Full Text] [Related]
42. Fragment Screening Yields a Small-Molecule Stabilizer of 14-3-3 Dimers That Modulates Client Protein Interactions.
Brink HJ; Riemens R; Thee S; Beishuizen B; da Costa Pereira D; Wijtmans M; de Esch I; Smit MJ; de Boer AH
Chembiochem; 2022 Sep; 23(17):e202200178. PubMed ID: 35767695
[TBL] [Abstract][Full Text] [Related]
43. Structurally constrained residues outside the binding motif are essential in the interaction of 14-3-3 and phosphorylated partner.
Uhart M; Iglesias AA; Bustos DM
J Mol Biol; 2011 Mar; 406(4):552-7. PubMed ID: 21216250
[TBL] [Abstract][Full Text] [Related]
44. Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions.
Valensin D; Cau Y; Calandro P; Vignaroli G; Dello Iacono L; Chiariello M; Mori M; Botta M
Bioorg Med Chem Lett; 2016 Feb; 26(3):894-898. PubMed ID: 26774582
[TBL] [Abstract][Full Text] [Related]
45. Chemical modulators working at pharmacological interface of target proteins.
Jeon YH; Lee JY; Kim S
Bioorg Med Chem; 2012 Mar; 20(6):1893-901. PubMed ID: 22227462
[TBL] [Abstract][Full Text] [Related]
46. New Compound Classes: Protein-Protein Interactions.
Ottmann C
Handb Exp Pharmacol; 2016; 232():125-38. PubMed ID: 26489828
[TBL] [Abstract][Full Text] [Related]
47. Druggable protein-protein interactions--from hot spots to hot segments.
London N; Raveh B; Schueler-Furman O
Curr Opin Chem Biol; 2013 Dec; 17(6):952-9. PubMed ID: 24183815
[TBL] [Abstract][Full Text] [Related]
48. Protein surface recognition and proteomimetics: mimics of protein surface structure and function.
Fletcher S; Hamilton AD
Curr Opin Chem Biol; 2005 Dec; 9(6):632-8. PubMed ID: 16242379
[TBL] [Abstract][Full Text] [Related]
49. Label-free screening of drug-protein interactions by time-resolved Fourier transform infrared spectroscopic assays exemplified by Ras interactions.
Kötting C; Suveyzdis Y; Bojja RS; Metzler-Nolte N; Gerwert K
Appl Spectrosc; 2010 Sep; 64(9):967-72. PubMed ID: 20828432
[TBL] [Abstract][Full Text] [Related]
50. Discovering functional interdependence relationship in PPI networks for protein complex identification.
Lam WW; Chan KC
IEEE Trans Biomed Eng; 2012 Apr; 59(4):899-908. PubMed ID: 21095855
[TBL] [Abstract][Full Text] [Related]
51. Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay.
Du Y; Masters SC; Khuri FR; Fu H
J Biomol Screen; 2006 Apr; 11(3):269-76. PubMed ID: 16699128
[TBL] [Abstract][Full Text] [Related]
52. Discovery of Small-Molecule Stabilizers of 14-3-3 Protein-Protein Interactions via Dynamic Combinatorial Chemistry.
Hartman AM; Elgaher WAM; Hertrich N; Andrei SA; Ottmann C; Hirsch AKH
ACS Med Chem Lett; 2020 May; 11(5):1041-1046. PubMed ID: 32435423
[TBL] [Abstract][Full Text] [Related]
53. 14-3-3 proteins: regulators of numerous eukaryotic proteins.
van Heusden GP
IUBMB Life; 2005 Sep; 57(9):623-9. PubMed ID: 16203681
[TBL] [Abstract][Full Text] [Related]
54. 14-3-3 proteins as potential therapeutic targets.
Zhao J; Meyerkord CL; Du Y; Khuri FR; Fu H
Semin Cell Dev Biol; 2011 Sep; 22(7):705-12. PubMed ID: 21983031
[TBL] [Abstract][Full Text] [Related]
55. Reversible Dual-Covalent Molecular Locking of the 14-3-3/ERRγ Protein-Protein Interaction as a Molecular Glue Drug Discovery Approach.
Somsen BA; Schellekens RJC; Verhoef CJA; Arkin MR; Ottmann C; Cossar PJ; Brunsveld L
J Am Chem Soc; 2023 Mar; 145(12):6741-6752. PubMed ID: 36926879
[TBL] [Abstract][Full Text] [Related]
56. Specific modulation of protein kinase activity via small peptides.
Costa-Junior HM; Suetsugu MJ; Krieger JE; Schechtman D
Regul Pept; 2009 Feb; 153(1-3):11-8. PubMed ID: 19135095
[TBL] [Abstract][Full Text] [Related]
57. Generating Potential Protein-Protein Interaction Inhibitor Molecules Based on Physicochemical Properties.
Ohue M; Kojima Y; Kosugi T
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570623
[TBL] [Abstract][Full Text] [Related]
58. Phage display as a method for discovering cellular targets of small molecules.
Van Dorst B; Mehta J; Rouah-Martin E; Blust R; Robbens J
Methods; 2012 Sep; 58(1):56-61. PubMed ID: 22819857
[TBL] [Abstract][Full Text] [Related]
59. The first small-molecule inhibitor of 14-3-3s: modulating the master regulator.
Kaiser M; Ottmann C
Chembiochem; 2010 Oct; 11(15):2085-7. PubMed ID: 20839267
[No Abstract] [Full Text] [Related]
60. The use of mammalian two-hybrid technologies for high-throughput drug screening.
Lievens S; Caligiuri M; Kley N; Tavernier J
Methods; 2012 Dec; 58(4):335-42. PubMed ID: 22917772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
